Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US ...
Bullous pemphigoid (BP), which has no FDA-approved ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any rescue therapy.
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Dupixent was previously granted Orphan Drug Designation by the FDA for Bullous pemphigoid, which applies to investigational medicines intended for the treatment of rare diseases that affect fewer ...
such as Dupixent for the treatment of adults with bullous pemphigoid as discussed in this press release as well as chronic pruritus of unknown origin, lichen simplex chronicus, and other potential ...
such as Dupixent for the treatment of adults with bullous pemphigoid as discussed in this press release as well as chronic pruritus of unknown origin, lichen simplex chronicus, and other potential ...
such as Dupixent for the treatment of adults with bullous pemphigoid as discussed in this press release as well as chronic pruritus of unknown origin, lichen simplex chronicus, and other potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback